Pax5 immunostaining in paraffin-embedded sections of canine non-Hodgkin lymphoma: A novel canine pan pre-B- and B-cell marker

Veterinary Immunology and Immunopathology

Volumn 128, Issue 4, 2009, Pages 359-365

  Willmann, M ^a   Mullauer L ^b   Guija de Arespacochaga, A ^a   Reifinger, M ^a   Mosberger, I ^b   Thalhammer, J G ^a  

^a UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

B cell marker; B lymphocytes; BSAP; Canine non Hodgkin lymphoma; Immunohistochemistry; Immunophenotyping; Pax5

Indexed keywords

CD3 ANTIGEN; CD79A ANTIGEN; PARAFFIN; PROTEIN ANTIBODY; TRANSCRIPTION FACTOR PAX5; TRANSCRIPTION FACTOR PAX5 ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; DOG; FEMALE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MALE; NONHODGKIN LYMPHOMA; NONHUMAN; PROTEIN EXPRESSION;

ANIMALS; B-CELL-SPECIFIC ACTIVATOR PROTEIN; B-LYMPHOCYTES; DOG DISEASES; DOGS; FEMALE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LYMPH NODES; LYMPHOMA, NON-HODGKIN; MALE; PARAFFIN EMBEDDING;

CANIS FAMILIARIS;

EID: 61349139933     PISSN: 01652427     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vetimm.2008.11.019     Document Type: Article

References (28)

1. Adams B., Dorfler P., Aguzzi A., Kozmik Z., Urbanek P., Maurer-Fogy I., and Busslinger M. Pax-5 encodes the transcription factor BSAP and is expressed in B lymphocytes, the developing CNS, and adult testis. Genes Dev. 6 (1992) 1589
2. Appelbaum F.R., Sale G.E., Storb R., Charrier K., Deeg H.J., Graham T., and Wulff J.C. Phenotyping of canine lymphoma with monoclonal antibodies directed at cell surface antigens: classification, morphology, clinical presentation and response to chemotherapy. Hematol. Oncol. 2 (1984) 151-168
3. Barberis A., Widenhorn K., Vitelli L., and Busslinger M. A novel B-cell lineage-specific transcription factor present at early but not late stages of differentiation. Genes Dev. 4 (1990) 849
4. Busslinger M., and Urbanek P. The role of BSAP (Pax-5) in B-cell development. Curr. Opin. Genet. Dev. 5 (1995) 595-601
5. Carter R.F., Valli V.E., and Lumsden J.H. The cytology, histology and prevalence of cell types in canine lymphoma classified according to the National Cancer Institute Working Formulation. Can. J. Vet. Res. 50 (1986) 154-164
6. Dobson J.M., Blackwood L.B., McInnes E.F., Bostock D.E., Nicholls P., Hoather T.M., and Tom B.D. Prognostic variables in canine multicentric lymphosarcoma. J. Small Anim. Pract. 42 (2001) 377-384
7. Foss H.D., Reusch R., Demel G., Lenz G., Anagnostopoulos I., Hummel M., and Stein H. Frequent expression of the B-cell-specific activator protein in Reed-Sternberg cells of classic Hodgkin's disease provides further evidence of its B-cell origin. Blood 94 (1999) 3108-3113
8. Fournel-Fleury C., Magnol J.P., Bricaire P., Marchal T., Chabanne L., Delverdier A., Bryon P.A., and Felman P. Cytohistological and immunological classification of canine malignant lymphomas: comparison with human non-Hodgkin's lymphomas. J. Comp. Pathol. 117 (1997) 35-59
9. Guija de Arespacochaga A., Schwendenwein I., and Weissenboeck H. Retrospective study of 82 cases of canine lymphoma in Austria based on the Working Formulation and immunophenotyping. J. Comp. Pathol. 136 (2007) 186-192
10. Horcher M., Souabni A., and Busslinger M. Pax5/BSAP maintains the identity of B cells in late B lymphopoiesis. Immunity 14 (2001) 779-790
11. Kehrl J.H., Riva A., Wilson G.L., and Thevenin C. Molecular mechanisms regulating CD19, CD20 and CD22 gene expression. Immunol. Today 15 (1994) 432-436
12. Krenacs L., Himmelmann A.W., Quintanilla-Martinez L., Fest T., Riva A., Wellmann A., Bagdi E., Kehrl J.H., Jaffe E.S., and Raffeld M. Transcription factor B-cell-specific activator protein (BSAP) is differentially expressed in B cells and in subsets of B-cell lymphomas. Blood 92 (1998) 1308-1316
13. Milner R.J., Pearson J., Nesbit J.W., and Close P. Immunophenotypic classification of canine malignant lymphoma on formalin-mixed paraffin wax-embedded tissue by means of CD3 and CD79a cell markers. Onderstepoort J. Vet. Res. 63 (1996) 309-313
14. Nutt S.L., Thevenin C., and Busslinger M. Essential functions of Pax-5 (BSAP) in pro-B cell development. Immunobiology 198 (1997) 227-235
15. Nutt S.L., Heavey B., Rolink A.G., and Busslinger M. Commitment to the B-lymphoid lineage depends on the transcription factor Pax5. Nature 401 (1999) 556-562
16. Pilozzi E., Müller-Hermelink H.K., Falini B., de Wolf-Peeters C., Fidler C., Gatter K., and Wainscoat J. Gene rearrangements in T-cell lymphoblastic lymphoma. J. Pathol. 188 (1999) 267-270
17. Ponce F., Magnol J.P., Ledieu D., Marchal T., Turinelli V., Chalvet-Monfray K., and Fournel-Fleury C. Prognostic significance of morphological subtypes in canine malignant lymphomas during chemotherapy. Vet. J. 167 (2004) 158-166
18. Ruslander D.A., Gebhard D.H., Tompkins M.G., Grindem C.B., and Page R.L. Immunophenotypic characterization of canine lymphoproliferative disorders. In Vivo 11 (1997) 169-172
19. Teske E., van Heerde P., Rutteman G.R., Kurzman I.D., Moore P.F., and MacEwen E.G. Prognostic factors for treatment of malignant lymphoma in dogs. J. Am. Vet. Med. Assoc. 205 (1994) 722-728
20. Teske E. Canine malignant lymphoma: a review and comparison with human non-Hodgkin's lymphoma. Vet. Q. 16 (1995) 209-219
21. Thomas R., Smith K.C., Gould R., Gower S.M., Binns M.M., and Breen M. Molecular cytogenetic analysis of a novel high-grade canine T-lymphoblastic lymphoma demonstrating co-expression of CD3 and CD79a cell markers. Chromosome Res. 9 (2001) 649-657
22. Torlakovic E., Torlakovic G., Nguyen P.L., Brunning R.D., and Delabie J. The value of anti-pax-5 immunostaining in routinely fixed and paraffin-embedded sections: a novel pan pre-B and B-cell marker. Am. J. Surg. Pathol. 26 (2002) 1343-1350
23. Usui T., Wakatsuki Y., Matsunaga Y., Kaneko S., Koseki H., and Kita T. Overexpression of B cell-specific activator protein (BSAP/Pax-5) in a late B cell is sufficient to suppress differentiation to an Ig high producer cell with plasma cell phenotype. J. Immunol. 158 (1997) 3197-3204
24. Vail D.M., Kisseberth W.C., Obradovich J.E., Moore F.M., London C.A., MacEwen E.G., and Ritter M.A. Assessment of potential doubling time (Tpot), argyrophilic nucleolar organizer regions (AgNOR), and proliferating cell nuclear antigen (PCNA) as predictors of therapy response in canine non-Hodgkin's lymphoma. Exp. Hematol. 24 (1996) 807-815
25. Valerius K.D., Ogilvie G.K., Mallinckrodt C.H., and Getzy D.M. Doxorubicin alone or in combination with asparaginase, followed by cyclophosphamide, vincristine, and prednisone for treatment of multicentric lymphoma in dogs: 121 cases (1987-1995). J. Am. Vet. Med. Assoc. 210 (1997) 512-516
26. Valli V.E., Jacobs R.M., Parodi A.L., Vernau W., and Moore P.F. WHO Histological Classification of Haematopoietic Tumours of Domestic Animals, second series vol. 3 (2002), Armed Forces Institute of Pathology, American Registry of Pathology, Washington, DC
27. Van Renterghem P., Vassart G., and Christophe D. Pax 8 expression in primary cultured dog thyrocyte is increased by cyclic AMP. Biochim. Biophys. Acta 1307 (1996) 97-103
28. Wilkerson M.J., Dolce K., Koopman T., Shuman W., Chun R., Garrett L., Barber L., and Avery A. Lineage differentiation of canine lymphoma/leukemias and abberant expression of CD molecules. Vet. Immunol. Immunopathol. 106 (2005) 179-196